ABUS Stock Analysis: Buy, Sell, or Hold?
ABUS - Arbutus Biopharma Corporation Common Stock
$4.58
-0.17 (-3.48%)
▼
5d:
-4.69%
30d:
+4.21%
90d:
-2.24%
BUY
MODERATE Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 05, 2026
18d
Smart Money Accumulation
None View Scanner →
Strength: 5.0/10
Get Alerted When ABUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ABUS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ABUS is currently trading at $4.58, which is considered fair relative to its 30-day fair value range of $4.32 to $4.89.
Technical Outlook: Technically, ABUS is showing sideways momentum. The price is currently testing key support at $4.46. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABUS is showing sideways momentum. The price is currently testing key support at $4.46. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$4.32 -
$4.89
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- NEUTRAL: Near Wall St target ($5.12)
Trading Range Analysis
30-Day Trading Range
$4.32 -
$4.89
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$4.46
Resistance Level
$5.38
Current Trend
Sideways
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-38.23
Wall Street Target
$5.12
(+7.9%)
Revenue Growth (YoY)
10054.5%
Profit Margin
84.0%
Share & Embed Analysis
Last updated: July 17, 2026 3:43 PM ET
Data refreshes hourly during market hours. Next update: 4:43 PM
Data refreshes hourly during market hours. Next update: 4:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 60 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 54 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 52 HOLD |
Advanced ABUS Option Strategies
Professional options setups generated by AI based on today's ABUS price and gamma walls.
